The most significant addition was AstraZeneca PLC (NYSE:AZN), with 10,845,708 shares, accounting for 0.73% of the portfolio and a total value of $2.14 billion. The second largest addition to the ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for ...

Is AZN a good stock to buy? We came across a bullish thesis on AstraZeneca PLC on South Sea Investing’s Substack. In this ...

AstraZeneca Plc AZN on Wednesday reported first-quarter 2026 results that topped Wall Street estimates, driven by strong ...

Learn more about whether AstraZeneca PLC or Elanco Animal Health Incorporated is a better investment based on AAII's A+ ...

AstraZeneca (AZN) shares dip despite beating Q1 forecasts with $15.29B revenue. Analysts say strong results were already ...

Welcome to AstraZeneca's Q1 2026 Webinar for Investors and Analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor ...

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers versus placebo on standard care.

AstraZeneca PLC AZN shares dropped 3.13% to £135.12 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.14% to 10,363.93.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging ...